Corbus Pharmaceuticals Holdings, Inc. announced the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002), a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4. The Phase 1 portion of the open label study design (NCT06265727), being conducted in the U.S. and Europe, will evaluate the safety, efficacy and pharmacokinetics (PK) of CRB-701 in participants with advanced solid tumors associated with high Nectin-4 expression. The Phase 1 trial initiates with dose escalation followed by dose optimization and concludes with dose expansion to determine the recommended Phase 2 dose.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.04 USD | +3.93% | -1.85% | +513.25% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+513.25% | 374M | |
-3.46% | 102B | |
+1.41% | 96.29B | |
+2.13% | 22.18B | |
-15.84% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.65% | 16.36B | |
+4.39% | 13.97B | |
+31.35% | 12.17B |
- Stock Market
- Equities
- CRBP Stock
- News Corbus Pharmaceuticals Holdings, Inc.
- Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC